Linked Life Data

21054464

Source:http://linkedlifedata.com/resource/pubmed/id/21054464

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21054464rdf:typepubmed:Citationlld:pubmed
pubmed-article:21054464lifeskim:mentionsumls-concept:C0152035lld:lifeskim
pubmed-article:21054464lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:21054464lifeskim:mentionsumls-concept:C0079488lld:lifeskim
pubmed-article:21054464lifeskim:mentionsumls-concept:C0021755lld:lifeskim
pubmed-article:21054464lifeskim:mentionsumls-concept:C0002645lld:lifeskim
pubmed-article:21054464lifeskim:mentionsumls-concept:C0010798lld:lifeskim
pubmed-article:21054464lifeskim:mentionsumls-concept:C0028978lld:lifeskim
pubmed-article:21054464lifeskim:mentionsumls-concept:C0055856lld:lifeskim
pubmed-article:21054464lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:21054464lifeskim:mentionsumls-concept:C0378482lld:lifeskim
pubmed-article:21054464lifeskim:mentionsumls-concept:C0205174lld:lifeskim
pubmed-article:21054464lifeskim:mentionsumls-concept:C1521828lld:lifeskim
pubmed-article:21054464lifeskim:mentionsumls-concept:C1882417lld:lifeskim
pubmed-article:21054464pubmed:issue6lld:pubmed
pubmed-article:21054464pubmed:dateCreated2010-11-8lld:pubmed
pubmed-article:21054464pubmed:abstractTextWHAT IS KNOWN AND OBJECTIVE: Genetic polymorphism of interleukin (IL)-1? and IL-1 receptor antagonist (IL-1r?) are associated with efficacy of acid suppression, whereas cytochrome P (CYP) 2C19 polymorphism influences the metabolism of proton pump inhibitor family. Thus, CYP2C19 and IL-1 polymorphisms may affect the efficacy of H. pylori eradication therapy. We compared the efficacies of omeprazole and rabeprazole on eradication of H. pylori in relation to CYP2C19, IL-1B and IL-1RN genotypes in Chinese people. METHODS: Two hundred and forty Chinese with peptic ulcer disease were randomly assigned to the following regimens: amoxicillin and clarithromycin together with omeprazole (OAC) or rabeprazole (RAC). CYP2C19*2 and *3, IL1B-511, IL1B-31, IL1B+ 3954 and intron 2 of the IL-1RN genotypes were analyzed by polymerase chain reaction-restriction fragment length polymorphism. RESULTS: The intention-to-treat-based cure rate of the OAC regimen was significantly lower than that of the RAC regimen in the CYP2C19 wild-type homozygotes (P?=?0·014). No significant differences in the cure rates were observed among the IL-1RN and the IL-1B genotype groups. WHAT IS NEW AND CONCLUSIONS: The rabeprazole-based triple regimen was better than the omeprazole in Chinese patients with the CYP2C19 extensive metabolizer genotype. The effectiveness of the PPI/AC regimen is unrelated to IL-1B and IL1-RN genetic polymorphism.lld:pubmed
pubmed-article:21054464pubmed:languageenglld:pubmed
pubmed-article:21054464pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21054464pubmed:citationSubsetIMlld:pubmed
pubmed-article:21054464pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21054464pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21054464pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21054464pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21054464pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21054464pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21054464pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21054464pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21054464pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21054464pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21054464pubmed:statusMEDLINElld:pubmed
pubmed-article:21054464pubmed:monthDeclld:pubmed
pubmed-article:21054464pubmed:issn1365-2710lld:pubmed
pubmed-article:21054464pubmed:authorpubmed-author:HoY SYSlld:pubmed
pubmed-article:21054464pubmed:authorpubmed-author:ZhangLLlld:pubmed
pubmed-article:21054464pubmed:authorpubmed-author:MeeMMlld:pubmed
pubmed-article:21054464pubmed:authorpubmed-author:XuJ MJMlld:pubmed
pubmed-article:21054464pubmed:authorpubmed-author:LiQ SQSlld:pubmed
pubmed-article:21054464pubmed:copyrightInfo© 2010 Blackwell Publishing Ltd.lld:pubmed
pubmed-article:21054464pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21054464pubmed:volume35lld:pubmed
pubmed-article:21054464pubmed:ownerNLMlld:pubmed
pubmed-article:21054464pubmed:authorsCompleteYlld:pubmed
pubmed-article:21054464pubmed:pagination713-22lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:meshHeadingpubmed-meshheading:21054464...lld:pubmed
pubmed-article:21054464pubmed:year2010lld:pubmed
pubmed-article:21054464pubmed:articleTitleThe effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people.lld:pubmed
pubmed-article:21054464pubmed:affiliationDepartment of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, PR China.lld:pubmed
pubmed-article:21054464pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21054464pubmed:publicationTypeRandomized Controlled Triallld:pubmed
entrez-gene:1557entrezgene:pubmedpubmed-article:21054464lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:21054464lld:entrezgene